23:55 , Jun 12, 2019 |  BioCentury  |  Finance

How Bain plans to deploy $1B new fund

Bain Capital Life Sciences’ larger second fund could see the firm increasing its emphasis on investing in big biopharma spinouts after its debut fund featured investments in a pair of megarounds by Pfizer spin-offs. Bain...
22:23 , May 10, 2019 |  BC Extra  |  Financial News

May 10 Financial Quick Takes: Intercept raises over $400M; plus 28-7, LunaPBC

Intercept raises $410.4M via sales of stock, notes  Liver disease company Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) raised $200.4 million through the sale of 2.4 million shares at $83.50 in a follow-on, another $200 million through the...
20:04 , Apr 25, 2019 |  BC Innovations  |  Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for...
18:44 , Apr 12, 2019 |  BC Week In Review  |  Financial News

Bain files for new life sciences fund

Bain Capital is raising capital for its second life sciences fund, according to an SEC filing. The firm did not disclose in the filing how much it plans to raise for Bain Capital Life Sciences...
20:49 , Apr 11, 2019 |  BC Week In Review  |  Clinical News

Cerevel's GABA A modulator reduces photosensitivity in epilepsy patients

After spinning out of Pfizer in October to develop the pharma's discontinued neuroscience pipeline, Cerevel plans to begin by year end another Phase II trial of CVL-865 in broader epilepsy populations. Cerevel Therapeutics LLC (Boston,...
10:30 , Apr 1, 2019 |  BC Extra  |  Financial News

SpringWorks raises $125M series B round

A year and a half after raising its initial round of funding to develop programs spun out of Pfizer, SpringWorks has raised $125 million in a series B round. The company now has funding to...
21:56 , Feb 22, 2019 |  BioCentury  |  Politics, Policy & Law

Azar’s IPI: socialist or capitalist?

The Trump administration’s plan for an international reference pricing scheme for Medicare Part B drugs has provoked vituperative opposition from BIO, PhRMA and their allies who have branded it as an attempt to impose socialism....
00:50 , Jan 5, 2019 |  BC Extra  |  Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
00:29 , Dec 22, 2018 |  BC Extra  |  Financial News

Markets deliver biotech lump of coal

Biotech indexes fell about 4% on Friday, with CRISPR stocks taking a particularly hard hit, and ended the week down double digits as the broader market fell on macroeconomic concerns. Continued tension over a trade...
19:47 , Dec 21, 2018 |  BC Week In Review  |  Financial News

Annexon to use $75M series C to advance complement inhibitors to Phase II

Annexon Biosciences Inc. (South San Francisco, Calif.) raised $75 million in a series C round on Dec. 19 that the company said will fund development of its lead complement inhibitors through several clinical stages. Annexon...